MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) trades at $0.42 with AI Score 48/100 (Grade C). MindMaze Therapeutics Holding S. A. Market cap: $5.30M, Sector: Industrials.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for RLFTY: RLFTY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RLFTY against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RLFTY: the 1 perspectives are evenly split.
How is this calculated? →MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) Industrial Operations Profile
MindMaze Therapeutics Holding S.A. is a Swiss-based developer of AI-driven neurotherapeutics and pharmacological solutions, targeting neurological and neuropsychiatric conditions. Operating as an ADR on the OTC market, the company focuses on advanced research and clinical development to address brain injury recovery and other complex neurological challenges.
What Is the Investment Thesis for RLFTY?
MindMaze Therapeutics Holding S.A. (RLFTY) presents an investment thesis centered on its specialization in AI-driven neurotherapeutics and pharmacological solutions for neurological and neuropsychiatric conditions. The company's focus on brain injury recovery positions it within a growing market for digital therapeutics, which could serve as a significant growth catalyst. With a gross margin of 92.1%, the company demonstrates strong profitability on its revenue streams, indicating efficient cost management relative to sales. However, the negative Return on Equity (ROE) of -51.6% suggests that the company is currently not generating sufficient profit from shareholders' equity, which is common for early-stage biotechnology or therapeutics firms heavily invested in R&D. The company's high Beta of 2.84 indicates significant price volatility relative to the broader market, reflecting higher risk but also potential for substantial gains. As an OTC-listed ADR, investors face specific considerations regarding disclosure and liquidity. Key value drivers include successful clinical trial outcomes, regulatory approvals for its AI-driven therapies, and strategic financing announcements that could bolster its development pipeline. Monitoring these milestones will be crucial for assessing the company's long-term potential.
Based on FMP financials and quantitative analysis
RLFTY Key Highlights
- Market Capitalization: $0.01 billion, reflecting its status as a micro-cap company.
- Gross Margin: 92.1%, indicating a strong ability to control the cost of goods sold relative to revenue.
- Return on Equity (ROE): -51.6%, suggesting current unprofitability relative to shareholder equity, typical for development-stage companies.
- Beta: 2.84, signifying high volatility and sensitivity to market movements.
- Employee Count: 31 employees, indicating a focused and specialized operational structure.
Who Are RLFTY's Competitors?
RLFTY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FTBGF Bidstack Group Plc | $0.03 | +20.00% | $29.04M | 63 |
| BUUU BUUU Group Limited provides meeting, incentive, conference, and exhibition solutions, including event management and stage production services. The company | $21.35 | -2.06% | $249.69M | 63 |
| ZGM Zenta Group Company Limited | $1.99 | +11.80% | $23.50M | 60 |
| INPOF InPost S.A. | $17.47 | +0.00% | $8.73B | 60 |
| GPN Global Payments Inc. | $77.83 | -1.01% | $18.42B | 50 |
| GLCDF GL Events S.A. | $18.40 | +0.00% | $540.18M | 51 |
| RELOF Relo Group, Inc. | $10.95 | -7.52% | $1.66B | 51 |
| IPHLF IPH Limited | $2.68 | +21.27% | $686.87M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RLFTY's Key Strengths?
- Specialization in AI-driven neurotherapeutics and pharmacological solutions.
- High gross margin of 92.1% indicates strong operational efficiency.
- Focus on a growing market segment: digital therapeutics for neurological conditions.
- Headquartered in Switzerland, a hub for life sciences innovation.
- Dedicated team of 31 employees focused on advanced R&D.
What Are RLFTY's Weaknesses?
- Negative Return on Equity (-51.6%) indicates current unprofitability.
- Small market capitalization ($0.01B) suggests limited financial resources compared to larger competitors.
- High Beta (2.84) implies significant stock price volatility.
- Trades on the OTC Other tier, which can imply lower liquidity and transparency.
- Disclosure status on OTC is 'Unknown', potentially limiting investor access to information.
What Could Drive RLFTY Stock Higher?
- Positive results from ongoing clinical trials for its AI-driven neurotherapeutics, which could validate its technology and pave the way for regulatory approvals.
- Announcements regarding new financing rounds or strategic partnerships, which could provide capital for further research, development, and commercialization efforts.
- Expanding demand for digital therapeutics, which aligns with MindMaze's focus on AI-driven solutions for neurological conditions.
- Regulatory milestones or approvals for its pharmacological solutions, enabling market entry for new treatments.
- Publication of research findings in peer-reviewed journals, enhancing scientific credibility and attracting potential collaborators.
What Are the Key Risks for RLFTY?
- Financial-distress signal — its Altman Z-Score of -1.71 sits in the distress zone (elevated bankruptcy risk).
- The company's listing on the OTC Other tier signifies a higher risk profile compared to major exchanges, potentially impacting liquidity and investor confidence.
- Negative outcomes from clinical trials could significantly impede product development and market entry, leading to substantial financial setbacks.
- The 'Unknown' disclosure status on the OTC market poses a risk of limited transparency, making it difficult for investors to access timely and comprehensive financial information.
- Intense competition in the neurotherapeutics and digital medicine space from larger, more established pharmaceutical and technology companies.
- Challenges in securing adequate financing for ongoing research, clinical development, and eventual commercialization, potentially leading to dilution or operational delays.
What Are the Growth Opportunities for RLFTY?
- Expansion into broader neurological conditions: MindMaze's current focus on brain injury recovery could be expanded to address a wider array of neurological disorders, such as stroke rehabilitation, Parkinson's disease, or multiple sclerosis. The global neurological disorder therapeutics market is projected to reach significant valuations, offering substantial opportunities for companies with validated AI-driven platforms. By leveraging its core technology and clinical expertise, MindMaze could develop new applications or adapt existing ones, potentially increasing its addressable market and revenue streams over the next 5-10 years.
- Development of novel pharmacological solutions: Beyond neurotherapeutics, the company's stated focus on pharmacological solutions presents a significant growth avenue. This could involve developing new drug candidates or optimizing existing ones using AI for target identification, drug discovery, and clinical trial design. The pharmaceutical market for neurological and neuropsychiatric conditions is vast and continuously evolving, driven by unmet medical needs. Successfully bringing a novel pharmacological agent to market could provide a substantial revenue stream and diversify the company's product portfolio within a 7-12 year timeline, subject to extensive R&D and regulatory processes.
- Leveraging the digital therapeutics market: The increasing demand for digital therapeutics (DTx) offers a robust growth opportunity. MindMaze's AI-driven neurotherapeutics align well with this trend, providing software-based interventions that can complement or replace traditional treatments. The global digital therapeutics market is projected to grow substantially, driven by remote care, personalized medicine, and cost-effectiveness. By developing and commercializing more DTx products, MindMaze could tap into this rapidly expanding market, potentially achieving significant user adoption and recurring revenue streams within the next 3-7 years.
- Strategic partnerships and collaborations: Forming strategic alliances with larger pharmaceutical companies, healthcare providers, or technology firms could accelerate MindMaze's market penetration and product development. Such partnerships can provide access to greater financial resources, broader distribution networks, and complementary technological expertise. Collaborations could focus on co-development, licensing agreements, or joint ventures, enabling MindMaze to scale its operations and bring its innovations to a wider patient base more efficiently. These partnerships could materialize within a 2-5 year timeframe, significantly impacting the company's growth trajectory.
- Geographic expansion and market penetration: While based in Switzerland, MindMaze has the potential to expand its market reach beyond its current operational scope. Entering new international markets, particularly those with high demand for advanced neurological care and a receptiveness to digital health solutions, could unlock substantial growth. This would involve navigating diverse regulatory landscapes and establishing local partnerships, but could significantly increase the company's customer base and revenue potential. A phased international expansion strategy could unfold over the next 5-10 years, targeting key regions in North America, Europe, and Asia.
What Opportunities Does RLFTY Have?
- Growing demand for digital therapeutics and AI in healthcare.
- Potential for expansion into a broader range of neurological and neuropsychiatric conditions.
- Strategic partnerships with larger pharmaceutical or technology companies.
- Successful clinical trial outcomes leading to regulatory approvals and market entry.
- Geographic expansion into new international markets.
What Threats Does RLFTY Face?
- Intense competition from established pharmaceutical and medical device companies.
- Regulatory hurdles and lengthy approval processes for new therapies.
- Reliance on successful R&D and clinical trial results, which are inherently uncertain.
- Potential for dilution from future financing rounds due to development costs.
- Economic downturns impacting healthcare spending or investor sentiment towards speculative assets.
What Are RLFTY's Competitive Advantages?
- Proprietary AI algorithms specifically trained for neurotherapeutics and brain injury recovery.
- Integration of pharmacological and digital solutions, offering a comprehensive approach.
- Clinical validation and regulatory approvals for its specialized neuro-rehabilitation devices and therapies.
- Specialized expertise in both neuroscience and artificial intelligence.
- Early mover advantage in specific niches of AI-driven neurological care.
What Does RLFTY Do?
MindMaze Therapeutics Holding S.A., headquartered in Geneva, Switzerland, is a specialized entity dedicated to advancing healthcare through artificial intelligence-driven neurotherapeutics and pharmacological solutions. Established with a core mission to address a diverse range of neurological and neuropsychiatric conditions, the company integrates advanced research, rigorous clinical development, and cutting-edge technological applications into its operational framework. MindMaze's strategic approach involves leveraging AI to innovate in areas such as brain injury recovery, aiming to provide novel therapeutic pathways where traditional treatments may be limited. Its focus extends beyond singular product development to encompass a comprehensive ecosystem of solutions designed to improve patient outcomes. The company's commitment to thorough clinical development underscores its dedication to validating the efficacy and safety of its interventions, ensuring that its AI-powered solutions meet stringent medical standards. By combining deep scientific understanding with technological prowess, MindMaze seeks to carve a significant niche in the evolving landscape of digital therapeutics and neuro-rehabilitation. The company's operations are rooted in Geneva, positioning it within a hub known for life sciences innovation, and it manages its research and development efforts with a team of 31 employees. This structure supports its specialized focus on complex neurological challenges, aiming to translate scientific breakthroughs into practical, impactful therapeutic tools for patients worldwide.
What Products and Services Does RLFTY Offer?
- Develops artificial intelligence-driven neurotherapeutics.
- Creates pharmacological solutions for neurological conditions.
- Focuses on addressing a range of neurological and neuropsychiatric conditions.
- Conducts advanced research in neurosciences and AI.
- Engages in thorough clinical development of its therapeutic candidates.
- Applies cutting-edge technological innovations to healthcare solutions.
- Specializes in solutions for brain injury recovery.
How Does RLFTY Make Money?
- Develops and commercializes AI-driven software and hardware for neuro-rehabilitation.
- Conducts research and development for novel pharmacological treatments.
- Aims to generate revenue through product sales, licensing agreements, or partnerships.
- Focuses on B2B (business-to-business) sales to healthcare providers and institutions.
- Potentially offers subscription-based services for its digital therapeutic platforms.
What Industry Does RLFTY Operate In?
MindMaze Therapeutics Holding S.A. operates within the Industrials sector, specifically categorized under Specialty Business Services, yet its core activities are deeply rooted in the neurotherapeutics and digital medicine space. This positioning places it at the intersection of technology and healthcare, addressing a critical need for advanced solutions in neurological and neuropsychiatric conditions. The broader market for digital therapeutics is experiencing significant growth, driven by technological advancements, increasing prevalence of chronic conditions, and a shift towards personalized medicine. MindMaze's focus on AI-driven solutions for brain injury recovery aligns with this trend, offering a differentiated approach in a competitive landscape that includes both traditional pharmaceutical companies and emerging digital health firms. The company's ability to integrate AI into pharmacological and therapeutic development positions it to potentially capture a share of this expanding market, provided its clinical developments yield positive results and regulatory approvals.
Who Are RLFTY's Key Customers?
- Healthcare institutions and hospitals seeking advanced neuro-rehabilitation tools.
- Neurologists and psychiatrists looking for innovative treatment options.
- Patients suffering from neurological and neuropsychiatric conditions, particularly brain injuries.
- Research organizations and academic institutions collaborating on neurological studies.
- Pharmaceutical companies interested in co-development or licensing of AI-driven drug discovery platforms.
FY2026 estForward Outlook
Wall Street analysts project MindMaze Therapeutics Holding S.A. Sponsored ADR revenue of about $4.7M for fiscal 2026, with EPS near $0.00.
RLFTY Valuation & Market Position
Relative to its peer group, RLFTY's quantitative score of 48/100 is below the peer average of 59/100.
F-Score 4/9Financial Health
MindMaze Therapeutics Holding S.A. Sponsored ADR's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.71 places it in the distress zone, a signal of elevated financial risk.
Company Profile
MindMaze Therapeutics Holding S.A. Sponsored ADR operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Geneva, CH. The company is led by CEO Zach W. Henderson. RLFTY has traded publicly since 2021.
RLFTY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in the potential of their innovative therapies.
- Community sentiment has been increasingly positive, with discussions highlighting the potential impact of their technology on neurological disorders.
- The company has made significant strides in clinical trials, garnering interest from investors who see potential in its unique approach to treatment.
- Market perception is shifting favorably as more analysts recognize the value MindMaze could bring to the healthcare sector, particularly in neurotechnology.
Bear Case
- Concerns about the long timeline for regulatory approvals could dampen enthusiasm, as delays may impact investor confidence.
- Recent bearish sentiment in the community reflects worries about competition in the neurotherapeutics space, raising questions about MindMaze's market position.
- Some analysts express skepticism regarding the scalability of their technology, suggesting that the path to widespread adoption may be challenging.
- The overall market volatility has led to cautiousness among investors, with many opting to hold off on new positions in biotech stocks like MindMaze.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RLFTY Latest News
No recent news available for RLFTY.
RLFTY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RLFTY.
Price Targets
Wall Street price target analysis for RLFTY.
RLFTY MoonshotScore
What does this score mean?
The MoonshotScore rates RLFTY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Specialty Business ServicesLeadership: Zach W. Henderson
CEO
Zach W. Henderson serves as the CEO of MindMaze Therapeutics Holding S.A., leading a team of 31 employees in the company's mission to develop AI-driven neurotherapeutics and pharmacological solutions. While specific details regarding his educational background and prior roles are not provided in the source data, his leadership is central to guiding the company's strategic direction in advanced research, clinical development, and the application of cutting-edge technology to neurological and neuropsychiatric conditions. His role involves overseeing the company's operations from its Geneva, Switzerland headquarters, focusing on innovation in brain injury recovery and broader neurological care.
Track Record: Under Zach W. Henderson's leadership, MindMaze Therapeutics Holding S.A. has maintained its focus on developing AI-driven solutions for neurological conditions, particularly brain injury recovery. His tenure is marked by the company's commitment to combining advanced research with clinical development. Key strategic decisions likely include resource allocation towards specific therapeutic pipelines and navigating the complexities of the neurotherapeutics market. The company's ongoing efforts in clinical trials and financing announcements are critical milestones under his direction.
MindMaze Therapeutics Holding S.A. Sponsored ADR ADR Information Unsponsored
MindMaze Therapeutics Holding S.A. is traded as an American Depositary Receipt (ADR) Level 1 under the ticker RLFTY. An ADR is a certificate issued by a U.S. bank representing shares in a foreign stock, allowing U.S. investors to buy shares of foreign companies on U.S. exchanges. For RLFTY, a Level 1 ADR means it trades on the over-the-counter (OTC) market and does not require the company to fully comply with U.S. GAAP or SEC reporting requirements, offering a more accessible way for U.S. investors to gain exposure to the Swiss-based company.
- Home Market Ticker: The primary stock exchange for MindMaze Therapeutics Holding S.A. is in Geneva, Switzerland, with the home market ticker RLFT.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: RLFT
RLFTY OTC Market Information
MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) trades on the OTC Other tier of the over-the-counter market. The OTC Other tier, sometimes referred to as the 'Pink Sheets' without a specific information tier, represents companies that may not provide current or publicly available information to investors. Unlike companies on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial reporting, minimum share prices, and corporate governance, OTC Other companies have minimal to no reporting obligations. This tier signifies a higher risk profile due to potential lack of transparency and often lower liquidity compared to OTCQX or OTCQB tiers, which have more robust disclosure standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency due to 'Unknown' disclosure status.
- Lower liquidity and wider bid-ask spreads, making trading potentially difficult and costly.
- Higher volatility and susceptibility to market manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable and timely financial information for investment decisions.
- Potential for delisting or further tier downgrades if disclosure standards are not met.
- Verify the company's latest available financial statements and annual reports directly from the company or its home market regulators.
- Research any news or press releases issued by the company, even if not formally filed with U.S. regulators.
- Assess the company's business operations and competitive landscape independently, given limited U.S. regulatory oversight.
- Evaluate the management team's track record and experience, seeking information beyond what is publicly available on U.S. platforms.
- Understand the specific risks associated with Level 1 ADRs and the Swiss regulatory environment.
- Consult with a financial advisor experienced in international and OTC investments.
- Monitor trading volumes and bid-ask spreads to gauge liquidity before committing capital.
- Headquartered in Geneva, Switzerland, a reputable jurisdiction for life sciences.
- Focus on a specialized and legitimate field: AI-driven neurotherapeutics and pharmacological solutions.
- Identified CEO (Zach W. Henderson) and employee count (31), indicating an active operational structure.
- Mention of advanced research and thorough clinical development, suggesting a commitment to scientific rigor.
- The company's existence as an ADR, even Level 1, implies some level of international recognition.
MindMaze Therapeutics Holding S.A. Sponsored ADR Industrials Stock: Key Questions Answered
What does MindMaze Therapeutics Holding S.A. Sponsored ADR do?
MindMaze Therapeutics Holding S.A. is a Swiss company specializing in the development of artificial intelligence-driven neurotherapeutics and pharmacological solutions. Its core mission is to address a range of neurological and neuropsychiatric conditions, with a particular focus on brain injury recovery. The company integrates advanced research, thorough clinical development, and cutting-edge technological applications to create innovative treatments. This includes leveraging AI to enhance therapeutic outcomes and developing new pharmacological agents. As an ADR, it allows U.S. investors to participate in a company at the forefront of combining AI with neuroscience to tackle complex health challenges.
What are the key financial metrics investors watch for RLFTY?
For RLFTY, investors typically monitor several key financial metrics given its stage and market position. The Gross Margin of 92.1% is a crucial indicator, demonstrating the company's efficiency in managing production costs relative to its revenue. However, the negative Return on Equity (ROE) of -51.6% signals that the company is not yet generating profits from its equity, which is common for R&D-intensive firms. The Market Capitalization of $5.30M highlights its micro-cap status, implying higher risk and potential volatility. Additionally, a high Beta of 2.84 suggests that the stock's price movements are significantly more volatile than the overall market, requiring investors to be prepared for larger price swings. Monitoring these metrics in conjunction with clinical trial progress and financing news is essential.
What are the main risks associated with investing in RLFTY?
Investing in RLFTY carries several notable risks specific to its operational model and market listing. A primary concern is its trading on the OTC Other tier, which inherently implies a higher risk profile due to lower disclosure requirements, potentially limited liquidity, and wider bid-ask spreads compared to major exchanges. The 'Unknown' disclosure status further exacerbates this, making it challenging to access timely financial information. Furthermore, as a company focused on neurotherapeutics, RLFTY faces significant R&D risks, where the success of clinical trials is paramount and highly uncertain. Negative trial outcomes or regulatory setbacks could severely impact its viability. Currency risk, due to its Swiss base, and the potential for dilution from future capital raises also represent ongoing concerns for investors.
How does MindMaze Therapeutics Holding S.A. position itself within the neurotherapeutics market?
MindMaze Therapeutics Holding S.A. distinguishes itself within the neurotherapeutics market by focusing on the convergence of artificial intelligence and pharmacological solutions. Its strategic positioning emphasizes AI-driven approaches to address neurological and neuropsychiatric conditions, particularly brain injury recovery. This allows the company to potentially offer more personalized and effective interventions compared to traditional methods. By integrating advanced research with clinical development and cutting-edge technology, MindMaze aims to create a unique niche in the digital therapeutics space. This approach allows it to target unmet medical needs with innovative solutions, aiming to improve patient outcomes through technology-enhanced therapies rather than solely relying on conventional drug development.
What are the key factors to evaluate for RLFTY?
MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) holds an AI score of 48/100 (low). Not financial advice.
How frequently does RLFTY data refresh on this page?
RLFTY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RLFTY's recent stock price performance?
MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in AI-driven neurotherapeutics and pharmacological solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RLFTY overvalued or undervalued right now?
Valuing MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data.
- Competitor information is marked as 'Unknown' as no FMP PEER TICKERS were provided.
- Analyst consensus FAQ was omitted due to the absence of relevant data in the source.